Definium Therapeutics, Inc 8-K/A, filed Jul 25, 2023
Definium Therapeutics, Inc. (DFTX)
About this 8-K/A
Definium Therapeutics, Inc filed this 8-K/A on July 25, 2023, reporting on events of June 21, 2023.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
Set forth below are the final voting results for the Annual Meeting as certified by the Independent Inspector of Elections on July 25, 2023, as well as a description of the proposals voted on at the Annual Meeting. The results remain unchanged from the preliminary results the Company previously disclosed on the Original 8-K.
Final Voting Results
As of April 20, 2023, the record date for the Annual Meeting, 38,593,701 common shares were outstanding and entitled to vote at the Annual Meeting. A quorum was present at the Annual Meeting under the Company’s amended and restated articles, and there were 16,330,495 common shares present or represented at the Annual Meeting by valid proxies representing approximately 42.3% of the common shares entitled to vote at the Annual Meeting.
Proposal 1 – Election of Directors
The Company’s six nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, and Carol A. Vallone, were each elected to serve as a member of the Company’s Board of Directors (the “Board”) until the 2024 annual general meeting of shareholders (the “2024 Annual Meeting”) and until his or her successor is duly elected or qualified, by the following votes:
Company Board Nominee |
|
Votes For |
|
Votes |
Robert Barrow |
|
8,154,619 |
|
6,260,614 |
Dr. Suzanne Bruhn |
|
10,708,185 |
|
3,707,052 |
Dr. Roger Crystal |
|
8,208,815 |
|
6,206,151 |
David Gryska |
|
12,248,893 |
|
2,166,343 |
Andreas Krebs |
|
8,099,276 |
|
6,315,960 |
Carol A. Vallone |
|
8,125,466 |
|
6,289,772 |
|
|
|
|
|
FCM MM Holdings, LLC Nominee |
|
Votes For |
|
Votes |
Dr. Scott Freeman |
|
6,023,932 |
|
7,779,083 |
Dr. Farzin Farzaneh |
|
6,022,144 |
|
7,780,172 |
Vivek Jain |
|
5,950,387 |
|
7,852,629 |
Alexander J. Wodka |
|
5,921,398 |
|
7,881,619 |
Proposal 2 – Appointment of Auditor
The shareholders approved the appointment of KPMG LLP as the auditor of the Company until the close of the 2024 Annual Meeting, by the following votes:
Votes For |
|
Votes Against |
|
Votes Abstain |
14,857,596 |
|
394,019 |
|
1,078,880 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MIND MEDICINE (MINDMED) INC. |
|
|
|
|
|
Date: July 25, 2023 |
|
By: |
/s/ Robert Barrow |
|
|
Name: |
Robert Barrow |
|
|
Title: |
Chief Executive Officer |